Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 377
Filter
1.
Acta Med Indones ; 53(3): 326-330, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34611073

ABSTRACT

SARS CoV-2 virus has infected more than 200 million people worldwide and more than 4.4 million in Indonesia. The vaccination program has become one of the solutions launched by many countries globally, including Indonesia, to reduce the transmission rate of COVID-19. Various vaccination platforms are produced, such as inactivated, viral vector, mRNA, and protein subunit. The vaccination booster program with mRNA platform (Moderna) was launched by the Indonesian government to give better protection for health care workers, particularly from delta variant. In this case report, we discuss one of the typical side effects of Moderna vaccine, which is referred to as the COVID arm.


Subject(s)
Acetaminophen/administration & dosage , COVID-19 Vaccines , COVID-19/prevention & control , Drug-Related Side Effects and Adverse Reactions , Hypersensitivity, Delayed , Skin/pathology , 2019-nCoV Vaccine mRNA-1273 , Analgesics, Non-Narcotic/administration & dosage , Biopsy/methods , COVID-19/epidemiology , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/adverse effects , Drug-Related Side Effects and Adverse Reactions/etiology , Drug-Related Side Effects and Adverse Reactions/physiopathology , Drug-Related Side Effects and Adverse Reactions/therapy , Female , Fever/drug therapy , Fever/etiology , Humans , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/physiopathology , Hypersensitivity, Delayed/therapy , Injection Site Reaction/diagnosis , Injection Site Reaction/etiology , Injection Site Reaction/physiopathology , Middle Aged , Physicians , SARS-CoV-2 , Treatment Outcome , Vaccination/methods
2.
Allergy Asthma Proc ; 41(3): 158-166, 2020 05 01.
Article in English | MEDLINE | ID: mdl-32375959

ABSTRACT

Background: Recent studies demonstrated that, in the past few years, the number of jellyfish species is increasing worldwide; this increase can be explained by environmental and climatic reasons. Contacts with jellyfish can cause acute and chronic effects, including allergic reactions. Although anaphylaxis caused by jellyfish is a rare event, repetitive stings during bathing as well as marine sports and job activities represent important risk factors that can increase the probability of sensitization. Recently, it was also pointed out the possibility of anaphylaxis caused by jellyfish ingestion. In these cases, the sensitization could also be related to previous stings. In cases in which there is no history of jellyfish contact or ingestion, it has been hypothesized that there is a sensitization to an unknown cross-reactive antigen. Objective: The purpose of this work was to collect and review published studies and cases of anaphylaxis associated with jellyfish. Methods: We performed a medical literature data base search, which included English language articles published until September 2019, by using the key words "jellyfish" associated with "anaphylaxis" or "anaphylactic shock." Results: The results of our research showed that dangerous reactions can be caused both by contact and ingestion. Moreover, the latest changes in food habits, life style, and globalization could lead to a more frequent exposure to jellyfish both by contact and ingestion, and, consequently, to a higher probability of sensitization. Conclusion: Prospective studies and well-structured research are needed to better understand all the potential immunologic elements of jellyfish, to clarify its role in sensitization, and to avoid possible dangerous allergic reactions caused by cross-reactivity.


Subject(s)
Anaphylaxis/physiopathology , Bites and Stings/immunology , Cnidarian Venoms/immunology , Eating , Hydrozoa/immunology , Hypersensitivity, Delayed/physiopathology , Scyphozoa/immunology , Anaphylaxis/immunology , Animals , Humans , Hypersensitivity, Delayed/immunology , Hypersensitivity, Immediate/immunology , Hypersensitivity, Immediate/physiopathology , Immunization
3.
Dermatitis ; 31(3): 185-190, 2020.
Article in English | MEDLINE | ID: mdl-32217881

ABSTRACT

: Wine, beer, liquor, and spirits are widely consumed in many cultures across the globe, and for some individuals, ingestion, cutaneous contact, or other exposure can lead to dermatologic findings. However, there currently exist no comprehensive reviews on alcohol-related dermatitis. Herein, we will provide an overview of alcohol-related dermatitis and contact urticaria, including the epidemiology and clinical manifestations, potential allergens found in alcoholic beverages, testing approaches, and strategies for allergen avoidance.


Subject(s)
Alcoholic Beverages/adverse effects , Dermatitis, Allergic Contact/epidemiology , Urticaria/epidemiology , Balsams/adverse effects , Beer/adverse effects , Chromium/adverse effects , Citrus/adverse effects , Cobalt/adverse effects , Dermatitis/epidemiology , Dermatitis/physiopathology , Dermatitis/therapy , Dermatitis, Allergic Contact/etiology , Dermatitis, Allergic Contact/physiopathology , Dermatitis, Allergic Contact/therapy , Food Preservatives/adverse effects , Gold/adverse effects , Humans , Hypersensitivity, Delayed/epidemiology , Hypersensitivity, Delayed/etiology , Hypersensitivity, Delayed/physiopathology , Hypersensitivity, Delayed/therapy , Hypersensitivity, Immediate/epidemiology , Hypersensitivity, Immediate/etiology , Hypersensitivity, Immediate/physiopathology , Hypersensitivity, Immediate/therapy , Isothiocyanates/adverse effects , Nickel/adverse effects , Propylene Glycol/adverse effects , Sulfites/adverse effects , Urticaria/etiology , Urticaria/physiopathology , Urticaria/therapy , Wine/adverse effects
4.
Internist (Berl) ; 60(8): 821-839, 2019 Aug.
Article in German | MEDLINE | ID: mdl-31286163

ABSTRACT

Acute interstitial nephritis (AIN) is a rare, often underdiagnosed condition and a common cause of renal failure. Drugs are the leading cause. The underlying pathophysiological condition is often a type IV hypersensitivity reaction. There are also rarer idiopathic forms, which often remain unrecognized. Additionally, the pathophysiological mechanisms are poorly understood, so that only very few promising forms of treatment are available. For some medications the overall risk is low but the side effects are relevant for the clinical routine due to the fact that they are frequently prescribed. In addition, the development of new approaches, such as immunotherapy also leads to side effects that cannot be completely predicted. For many diseases the occurrence of acute kidney injury increases the mortality and morbidity. A potentially irreversible chronic renal failure increases the incidence of further comorbidities and reduces the quality of life. Treatment is difficult and mostly empirical.


Subject(s)
Acute Kidney Injury/etiology , Nephritis, Interstitial/complications , Nephritis, Interstitial/physiopathology , Renal Insufficiency, Chronic/etiology , Acute Kidney Injury/physiopathology , Drug-Related Side Effects and Adverse Reactions , Humans , Hypersensitivity, Delayed/complications , Hypersensitivity, Delayed/physiopathology , Nephritis, Interstitial/prevention & control , Quality of Life , Renal Insufficiency, Chronic/physiopathology
5.
Ann Vasc Surg ; 55: 239-245, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30217712

ABSTRACT

BACKGROUND: Cyanoacrylate closure for the treatment of incompetent saphenous veins does not cause thermal damage and demonstrates satisfactory outcomes with rapid recovery. However, the characteristics of phlebitis-like abnormal reaction (PLAR), the most common adverse event after cyanoacrylate closure, have not been clarified. Moreover, it differs from typical phlebitis after thermal ablation. The objective of our study is to investigate the clinical features of PLAR after cyanoacrylate closure and to report its management. METHODS: A total of 160 patients with 271 incompetent saphenous veins (great saphenous veins, 201; small saphenous veins, 70) underwent cyanoacrylate closure with the VenaSeal™ system. We defined PLAR as any unusual skin condition that develops suddenly, such as erythema, itching, swelling, and pain/tenderness, over the treated veins several days after cyanoacrylate closure. Oral antihistamines and intravenous dexamethasone were administered to manage PLAR. RESULTS: Of the 271 treated veins, 69 experienced PLAR (25.4%). The mean time of occurrence was 13.6 ± 4.6 days after treatment. The rate of occurrence of erythema, itching, swelling, and pain/tenderness were 92.2%, 91.2%, 66.2%, and 48.5%, respectively. The occurrence of PLAR was significantly higher for great saphenous veins than for small saphenous veins (P < 0.001). Occurrences were more frequent in cases with a suprafascial great saphenous vein of length >10 cm than in cases with a subfascial great saphenous vein (P = 0.001). The proportion of patients who reported swelling decreased by more than half after the administration of oral antihistamine. The pain score on the 10th day also decreased significantly after the administration of antihistamine (P = 0.006). CONCLUSIONS: PLAR must be distinguished from classic phlebitis. We believe that PLAR is a type IV hypersensitivity reaction due to a foreign body, and in our experience, antihistamines or steroids are effective for the prevention and management of PLAR.


Subject(s)
Cyanoacrylates/adverse effects , Foreign-Body Reaction/chemically induced , Hypersensitivity, Delayed/chemically induced , Phlebitis/chemically induced , Saphenous Vein , Tissue Adhesives/adverse effects , Venous Insufficiency/therapy , Administration, Intravenous , Administration, Oral , Adult , Aged , Dexamethasone/administration & dosage , Female , Foreign-Body Reaction/diagnostic imaging , Foreign-Body Reaction/drug therapy , Foreign-Body Reaction/physiopathology , Glucocorticoids/administration & dosage , Histamine Antagonists/administration & dosage , Humans , Hypersensitivity, Delayed/diagnostic imaging , Hypersensitivity, Delayed/drug therapy , Hypersensitivity, Delayed/physiopathology , Male , Middle Aged , Phlebitis/diagnostic imaging , Phlebitis/drug therapy , Phlebitis/physiopathology , Prospective Studies , Risk Factors , Saphenous Vein/diagnostic imaging , Saphenous Vein/physiopathology , Time Factors , Treatment Outcome , Venous Insufficiency/diagnostic imaging , Venous Insufficiency/physiopathology , Young Adult
6.
Contact Dermatitis ; 80(2): 118-124, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30311217

ABSTRACT

BACKGROUND: Anaphylaxis-like reactions developing within a few minutes are the most frequent complications of subcutaneous or submucosal injections of local anaesthetics (LAs), and topically applied LAs are potential contact allergens. In addition, injected LAs have been reported to induce delayed reactions, including local inflammation at the injection site, and various general symptoms. OBJECTIVES: To assess the frequency and symptoms of late-type hypersensitivity occurring several hours after LA injections. METHODS: We retrospectively evaluated clinical data and test results from all patients referred to our allergy clinic in a period of 20 years for diagnostic work-up of LA-associated late-type reactions. RESULTS: Of 202 patients reporting symptoms with onset at least 1 hour after LA injection, 40 had cutaneous inflammation confined to the injection site, and 162 reported various systemic symptoms. LA hypersensitivity could be excluded in all patients with systemic complaints by means of skin testing and subsequent subcutaneous provocation. In 8 of the 40 patients (20%) with local inflammatory reactions, late-type allergic LA hypersensitivity was confirmed. CONCLUSIONS: Late-type LA allergy commonly causes inflammatory skin reactions confined to the injection site. Conversely, LAs are highly unlikely to trigger delayed systemic symptoms such as urticarial or exanthematous skin eruptions.


Subject(s)
Anesthetics, Local/adverse effects , Drug Hypersensitivity/diagnosis , Hypersensitivity, Delayed/diagnosis , Injection Site Reaction/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Anaphylaxis/chemically induced , Anesthetics, Local/administration & dosage , Child , Child, Preschool , Diagnosis, Differential , Drug Eruptions/etiology , Drug Hypersensitivity/etiology , Drug Hypersensitivity/physiopathology , Female , Humans , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/physiopathology , Inflammation , Injection Site Reaction/etiology , Injection Site Reaction/physiopathology , Injections, Subcutaneous , Male , Middle Aged , Retrospective Studies , Skin Tests , Urticaria/chemically induced , Young Adult
9.
J Biol Chem ; 291(7): 3359-70, 2016 Feb 12.
Article in English | MEDLINE | ID: mdl-26721885

ABSTRACT

We have shown previously that collagen V (col(V)) autoimmunity is a consistent feature of atherosclerosis in human coronary artery disease and in the Apoe(-/-) mouse model. We have also shown sensitization of Apoe(-/-) mice with col(V) to markedly increase the atherosclerotic burden, providing evidence of a causative role for col(V) autoimmunity in atherosclerotic pathogenesis. Here we sought to determine whether induction of immune tolerance to col(V) might ameliorate atherosclerosis, providing further evidence for a causal role for col(V) autoimmunity in atherogenesis and providing insights into the potential for immunomodulatory therapeutic interventions. Mucosal inoculation successfully induced immune tolerance to col(V) with an accompanying reduction in plaque burden in Ldlr(-/-) mice on a high-cholesterol diet. The results therefore demonstrate that inoculation with col(V) can successfully ameliorate the atherosclerotic burden, suggesting novel approaches for therapeutic interventions. Surprisingly, tolerance and reduced atherosclerotic burden were both dependent on the recently described IL-35 and not on IL-10, the immunosuppressive cytokine usually studied in the context of induced tolerance and amelioration of atherosclerotic symptoms. In addition to the above, using recombinant protein fragments, we were able to localize two epitopes of the α1(V) chain involved in col(V) autoimmunity in atherosclerotic Ldlr(-/-) mice, suggesting future courses of experimentation for the characterization of such epitopes.


Subject(s)
Atherosclerosis/prevention & control , Autoimmunity , Collagen Type V/therapeutic use , Hypersensitivity, Delayed/prevention & control , Immune Tolerance , Interleukins/metabolism , Administration, Intranasal , Animals , Antibodies, Neutralizing/administration & dosage , Antibodies, Neutralizing/metabolism , Atherosclerosis/etiology , Atherosclerosis/immunology , Atherosclerosis/metabolism , Cattle , Cells, Cultured , Collagen Type V/administration & dosage , Collagen Type V/chemistry , Collagen Type V/genetics , Diet, Western/adverse effects , Epitope Mapping , Humans , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/metabolism , Hypersensitivity, Delayed/physiopathology , Immunity, Mucosal , Interleukins/antagonists & inhibitors , Mice, Inbred C57BL , Mice, Knockout , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/metabolism , Receptors, LDL/genetics , Receptors, LDL/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Spleen/immunology , Spleen/metabolism , Spleen/pathology
10.
J Allergy Clin Immunol ; 135(3): 589-96; quiz 597, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25747720

ABSTRACT

Anaphylaxis is a severe allergic reaction that can be rapidly progressing and fatal, and therefore establishing its cause is pivotal to long-term risk management. Our recent work has identified a novel IgE antibody response to a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). IgE to alpha-gal has been associated with 2 distinct forms of anaphylaxis: (1) immediate-onset anaphylaxis during first exposure to intravenous cetuximab and (2) delayed-onset anaphylaxis 3 to 6 hours after ingestion of mammalian food products (eg, beef and pork). Results of our studies and those of others strongly suggest that tick bites are a cause, if not the only significant cause, of IgE antibody responses to alpha-gal in the southern, eastern, and central United States; Europe; Australia; and parts of Asia. Typical immune responses to carbohydrates are considered to be T-cell independent, whereas IgE antibody production is thought to involve sequential class-switching that requires input from T cells. Therefore, establishing the mechanism of the specific IgE antibody response to alpha-gal will be an important aspect to address as this area of research continues.


Subject(s)
Anaphylaxis/immunology , Disaccharides/immunology , Food Hypersensitivity/immunology , Hypersensitivity, Delayed/immunology , Meat , Tick Bites/immunology , Allergens/immunology , Anaphylaxis/chemically induced , Anaphylaxis/diagnosis , Anaphylaxis/physiopathology , Animals , Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents/adverse effects , Cattle , Cetuximab , Epitopes/immunology , Food Hypersensitivity/diagnosis , Food Hypersensitivity/physiopathology , Humans , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Delayed/physiopathology , Immunoglobulin E/blood , Swine , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Tick Bites/diagnosis , Tick Bites/physiopathology
11.
Photochem Photobiol Sci ; 14(4): 801-6, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25645888

ABSTRACT

Ultraviolet (UV) wavelengths in sunlight are the prime cause of skin cancer in humans with both the UVA and UVB wavebands making a contribution to photocarcinogenesis. UV has many different biological effects on the skin that contribute to carcinogenesis, including suppression of adaptive immunity, sunburn and altering the migration of mast cells into and away from irradiated skin. Many molecular mechanisms have been identified as contributing to skin responses to UV. Recently, using gene set enrichment analysis of microarray data, we identified the alternative complement pathway with a central role for factor B (fB) in UVA-induced immunosuppression. In the current study we used mice genetically deficient in fB (fB-/- mice) to study the functional role of the alternative complement pathway in skin responses to UV. We found that fB is required for not only UVA but also UVB-induced immunosuppression and solar-simulated UV induction of the oedemal component of sunburn. Factor B-/- mice had a larger number of resident skin mast cells than control mice, but unlike the controls did not respond to UV by increasing mast cell infiltration into the skin. This study provides evidence for a function role for fB in skin responses to UV radiation. Factor B regulates UVA and UVB induced immunosuppression, UV induced oedema and mast cell infiltration into the skin. The alternative complement pathway is therefore an important regulator of skin responses to UV.


Subject(s)
Complement Factor B/metabolism , Edema/physiopathology , Hypersensitivity, Delayed/physiopathology , Mast Cells/radiation effects , Skin/radiation effects , Ultraviolet Rays/adverse effects , Animals , Cell Movement/physiology , Cell Movement/radiation effects , Complement Factor B/genetics , Disease Models, Animal , Edema/etiology , Female , Hypersensitivity, Delayed/etiology , Male , Mast Cells/physiology , Mice, Inbred C57BL , Mice, Knockout , Skin/physiopathology , Sunburn/etiology , Sunburn/physiopathology
13.
Lab Invest ; 94(7): 716-25, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24791744

ABSTRACT

The formation of unstable, leaky neovessels underlies the pathogenesis of many chronic inflammatory diseases. Granzyme B (GZMB) is an immune-derived serine protease that accumulates in the extracellular matrix (ECM) during chronic inflammation and is capable of cleaving fibronectin (FN). Vascular endothelial growth factor (VEGF) is a potent vascular permeabilizing agent that is sequestered in the ECM through its interaction with FN. As GZMB levels are elevated in chronic inflammatory diseases that are associated with increased vascular permeability, the role of GZMB in the regulation of VEGF bioavailability and vascular permeability were assessed. GZMB was added to either VEGF bound to FN or VEGF bound to endothelial cell (EC)-derived ECM. Supernatants containing released VEGF were assessed to determine VEGF activity by treating EC and evaluating VEGF receptor-2 (VEGFR2) phosphorylation. GZMB released VEGF from both FN and from EC-derived matrix, whereas GZMB inhibition prevented FN cleavage and VEGF release. GZMB-mediated VEGF release resulted in significant phosphorylation of VEGFR2. The role of GZMB-mediated VEGF release in altering vascular permeability was also assessed in vivo using Miles/Evans blue permeability assay. GZMB induced a significant VEGF-dependent increase in vascular permeability in vivo that was reduced in the presence of an anti-VEGF-neutralizing antibody. Inflammatory-mediated vascular leakage was also assessed in GZMB-KO mice using a delayed-type hypersensitivity model. GZMB-KO mice exhibited reduced microvascular leakage compared with C57\B6 controls. GZMB increases vascular permeability in part through the proteolytic release of ECM-sequestered VEGF, leading to VEGFR2 activation and increased vascular permeability in vivo. These findings present a novel role for GZMB as a modulator of vascular response during chronic inflammation.


Subject(s)
Capillary Permeability/physiology , Extracellular Matrix/metabolism , Granzymes/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Antibodies, Blocking/pharmacology , Blotting, Western , Capillary Permeability/drug effects , Capillary Permeability/genetics , Cells, Cultured , Extracellular Matrix/drug effects , Fibronectins/blood , Fibronectins/metabolism , Granzymes/genetics , Granzymes/pharmacology , Human Umbilical Vein Endothelial Cells/drug effects , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Hypersensitivity, Delayed/genetics , Hypersensitivity, Delayed/metabolism , Hypersensitivity, Delayed/physiopathology , Inflammation/genetics , Inflammation/metabolism , Inflammation/physiopathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Fluorescence , Vascular Endothelial Growth Factor A/immunology , Vascular Endothelial Growth Factor Receptor-2/metabolism
14.
Clin Rev Allergy Immunol ; 46(3): 225-40, 2014 Jun.
Article in English | MEDLINE | ID: mdl-23229594

ABSTRACT

Food allergy is defined as an adverse immune response towards food proteins or as a form of a food intolerance associated with a hypersensitive immune response. It should also be reproducible by a double-blind placebo-controlled food challenge. Many reported that food reactions are not allergic but are intolerances. Food allergy often presents to clinicians as a symptom complex. This review focuses on the clinical spectrum and manifestations of various forms of food allergies. According to clinical presentations and allergy testing, there are three types of food allergy: IgE mediated, mixed (IgE/Non-IgE), and non-IgE mediated (cellular, delayed type hypersensitivity). Recent advances in food allergy in early childhood have highlighted increasing recognition of a spectrum of delayed-onset non-IgE-mediated manifestation of food allergy. Common presentations of food allergy in infancy including atopic eczema, infantile colic, and gastroesophageal reflux. These clinical observations are frequently associated with food hypersensitivity and respond to dietary elimination. Non-IgE-mediated food allergy includes a wide range of diseases, from atopic dermatitis to food protein-induced enterocolitis and from eosinophilic esophagitis to celiac disease. The most common food allergies in children include milk, egg, soy, wheat, peanut, treenut, fish, and shellfish. Milk and egg allergies are usually outgrown, but peanut and treenut allergy tends to persist. The prevalence of food allergy in infancy is increasing and may affect up to 15-20 % of infants. The alarming rate of increase calls for a public health approach in the prevention and treatment of food allergy in children.


Subject(s)
Food Hypersensitivity/physiopathology , Hypersensitivity, Delayed/physiopathology , Celiac Disease/physiopathology , Child, Preschool , Colic/physiopathology , Dermatitis, Atopic/physiopathology , Enterocolitis/physiopathology , Eosinophilic Esophagitis/physiopathology , Food Hypersensitivity/diagnosis , Food Hypersensitivity/epidemiology , Food Hypersensitivity/immunology , Gastroesophageal Reflux/physiopathology , Humans , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Delayed/epidemiology , Hypersensitivity, Delayed/immunology , Immunoglobulin E/blood , Infant , Prevalence
15.
Pediatr Allergy Immunol ; 25(1): 80-7, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24329898

ABSTRACT

INTRODUCTION: Hypersensitivity reactions to beta-lactams (BLs) are often reported in children, with amoxicillin and, to a lesser extent, cephalosporins being the most frequent drugs involved. Although many of these children are considered to be allergic, a careful evaluation only confirms a low percentage. OBJECTIVES: To analyse the clinical data, sensitization profile and diagnostic methods used in a large group of children with a clinical history of hypersensitivity reactions to BLs. METHODS: The study included children aged 1-14 yr with symptoms suggestive of hypersensitivity to BLs from January 2006-December 2012. Diagnosis was confirmed from a clinical history, specific IgE determination, skin testing and, if necessary, a drug provocation test (DPT). RESULTS: Of a total of 783 patients studied, only 62 (7.92%) were confirmed as being allergic, 9 (14.52%) with immediate and 53 (85.48%) with non-immediate reactions. In those with immediate reactions, 2 (22.22%) were diagnosed by in vitro test, 2 (22.22%) by skin testing and 5 (55.56%) by DPT; in those with non-immediate reactions, 2 (3.77%) were diagnosed by skin testing and 51 (96.23%) by DPT. In all cases, DPT was positive to the culprit drug (29 AX-CLV, 26 AX, 1 cefixime and 1 cefaclor), and the most usual symptoms were exanthema in 43 cases, urticaria in 12, urticaria-angio-oedema in 1 and erythema in 1 case. CONCLUSION: After an allergological work-up, over 90% of the children evaluated were finally confirmed as tolerant to BLs. Most reactions were of the non-immediate type, and DPT was an essential tool for diagnosis.


Subject(s)
Drug Hypersensitivity/diagnosis , Exanthema/diagnosis , Hypersensitivity, Delayed/diagnosis , Population Groups , beta-Lactams/therapeutic use , Adolescent , Amoxicillin/administration & dosage , Amoxicillin/adverse effects , Cephalosporins/administration & dosage , Cephalosporins/adverse effects , Child , Child, Preschool , Drug Hypersensitivity/immunology , Drug Hypersensitivity/physiopathology , Exanthema/immunology , Exanthema/physiopathology , Female , Humans , Hypersensitivity, Delayed/immunology , Hypersensitivity, Delayed/physiopathology , Immunization , Immunoglobulin E/blood , Infant , Male , Skin Tests , beta-Lactams/adverse effects
16.
Dent Clin North Am ; 57(4): 583-96, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24034067

ABSTRACT

Erythema multiforme (EM) is an acute, immune-mediated disorder affecting the skin and/or mucous membranes, including the oral cavity. Target or iris lesions distributed symmetrically on the extremities and trunk characterize the condition. Infections are the most common cause of EM and the most frequently implicated infectious agent causing clinical disease is the herpes simplex virus. The diagnosis of EM is typically based on the patient's history and clinical findings. Management involves controlling the underlying infection or causative agent, symptom control, and adequate hydration. The epidemiology, pathogenesis, clinical features, diagnosis, and treatment of EM are reviewed in this article.


Subject(s)
Erythema Multiforme , Herpes Simplex/complications , Mucous Membrane/pathology , Oral Ulcer/pathology , Erythema Multiforme/diagnosis , Erythema Multiforme/etiology , Erythema Multiforme/physiopathology , Humans , Hypersensitivity, Delayed/physiopathology , Skin/pathology
17.
Br J Pharmacol ; 169(5): 1011-23, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23594188

ABSTRACT

BACKGROUND AND PURPOSE: The intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) modulates the Ca(2+) response through the control of the membrane potential in the immune system. We investigated the role of K(Ca)3.1 on the pathogenesis of delayed-type hypersensitivity (DTH) in auricular lymph node (ALN) CD4(+) T-lymphocytes of oxazolone (Ox)-induced DTH model mice. EXPERIMENTAL APPROACH: The expression patterns of K(Ca)3.1 and its possible transcriptional regulators were compared among ALN T-lymphocytes of three groups [non-sensitized (Ox-/-), Ox-sensitized, but non-challenged (Ox+/-) and Ox-sensitized and -challenged (Ox+/+)] using real-time polymerase chain reaction, Western blotting and flow cytometry. KCa 3.1 activity was measured by whole-cell patch clamp and the voltage-sensitive dye imaging. The effects of K(Ca)3.1 blockade were examined by the administration of selective K(Ca)3.1 blockers. KEY RESULTS: Significant up-regulation of K(Ca)3.1a was observed in CD4(+) T-lymphocytes of Ox+/- and Ox+/+, without any evident changes in the expression of the dominant-negative form, K(Ca)3.1b. Negatively correlated with this, the repressor element-1 silencing transcription factor (REST) was significantly down-regulated. Pharmacological blockade of K(Ca)3.1 resulted in an accumulation of the CD4(+) T-lymphocytes of Ox+/+ at the G0/G1 phase of the cell cycle, and also significantly recovered not only the pathogenesis of DTH, but also the changes in the K(Ca)3.1 expression and activity in the CD4(+) T-lymphocytes of Ox+/- and Ox+/+. CONCLUSIONS AND IMPLICATIONS: The up-regulation of K(Ca)3.1a in conjunction with the down-regulation of REST may be involved in CD4(+) T-lymphocyte proliferation in the ALNs of DTH model mice; and K(Ca)3.1 may be an important target for therapeutic intervention in allergy diseases such as DTH.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Hypersensitivity, Delayed/immunology , Intermediate-Conductance Calcium-Activated Potassium Channels/immunology , Adjuvants, Immunologic , Animals , CD4-Positive T-Lymphocytes/physiology , Cell Cycle/drug effects , Disease Models, Animal , Ear Auricle/immunology , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/physiopathology , Intermediate-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors , Intermediate-Conductance Calcium-Activated Potassium Channels/physiology , Lymph Nodes/immunology , Male , Mice, Inbred BALB C , Oxazolone , Potassium Channel Blockers/pharmacology , Pyrazoles/pharmacology , Repressor Proteins/immunology
19.
Arch Pharm Res ; 35(9): 1685-91, 2012 Sep.
Article in English | MEDLINE | ID: mdl-23054726

ABSTRACT

The adjuvant effect of icariin from Epimedium koreanum on the immune responses to bovine serum albumin (BSA) in mice was examined. Mice were immunized on days 1 and 22 intraperitoneally (i.p.) with one of the following: an emulsion form of BSA mixed with Incomplete Freund's Adjuvant (BSA/IFA) or with Complete Freund's Adjuvant (BSA/CFA) or BSA plus icariin mixed with IFA (BSA/Icariin/IFA). One week after the booster, polyclonal sera were collected from these animals to determine IgG isotypes specific for BSA in the sera and then spleens of these animals were harvested to evaluate IFN-γ and IL-4 produced in the splenocyte cultures. In order to determine the DTH (delayed type hypersensitivity) response, BSA was administered into the footpads of mice that were immunized as described above and the degree of footpad-swelling was measured. Data from these experiments showed that the icariin combined with BSA (BSA/Icariin/IFA) provoked the most abundant of IgG production in mice and enhanced the Th1-lineage development of IgG2a and IFN-γ productions (p < 0.05), whereas BSA/IFA resulted in a highest ratio of IgG1 to IgG2 and most dominant IL-4 production, indicating a Th2 response. This pattern of immunity was confirmed by the DTH determination revealing that icariin-containing formula caused the highest footpad-swelling followed by BSA/CFA and BSA/IFA, respectively. In addition, hemolytic assay showed that icariin at a dose of 1000 µg/mL caused no hemolysis when compared with a water-treated mouse. All of these data indicate that icariin has the immunoadjuvant effect which may enhance Th1-immune response, suggesting that icariin as an adjuvant would be beneficial in the treatment of Th1-disordered diseases.


Subject(s)
Adjuvants, Immunologic/administration & dosage , Flavonoids/administration & dosage , Hypersensitivity, Delayed/immunology , Immunity, Cellular , Th1 Cells/immunology , Adjuvants, Immunologic/adverse effects , Animals , Cells, Cultured , Female , Flavonoids/adverse effects , Hemolysis , Hypersensitivity, Delayed/blood , Hypersensitivity, Delayed/physiopathology , Immunoglobulin G/analysis , Injections, Intraperitoneal , Interferon-gamma Release Tests , Interleukin-4/metabolism , Mice , Mice, Inbred BALB C , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/adverse effects , Severity of Illness Index , Spleen/cytology , Spleen/immunology , Spleen/metabolism , Th1 Cells/cytology , Th1 Cells/metabolism , Th2 Cells/cytology , Th2 Cells/immunology , Th2 Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL